Next Article in Journal
Kinetic Analysis and Epitope Mapping of Monoclonal Antibodies to Salmonella Typhimurium Flagellin Using a Surface Plasmon Resonance Biosensor
Next Article in Special Issue
IgG Charge: Practical and Biological Implications
Previous Article in Journal
Evaluation of the NovaLisa™ Leishmania Infantum IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country
Previous Article in Special Issue
IgE Antibodies: From Structure to Function and Clinical Translation
Article Menu

Export Article

Open AccessReview

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies

Department of Pharmaceutical Sciences, Utrecht University, 3512 JE Utrecht, The Netherlands
*
Author to whom correspondence should be addressed.
Antibodies 2019, 8(1), 21; https://doi.org/10.3390/antib8010021
Received: 13 February 2019 / Accepted: 27 February 2019 / Published: 5 March 2019
(This article belongs to the Special Issue Structure and Function of Antibodies)
  |  
PDF [221 KB, uploaded 8 March 2019]

Abstract

The development of hybridoma technology for producing monoclonal antibodies (mAbs) by Kohler and Milstein (1975) counts as one of the major medical breakthroughs, opening up endless possibilities for research, diagnosis and for treatment of a whole variety of diseases. Therapeutic mAbs were introduced three decades ago. The first generation of therapeutic mAbs of murine origin showed high immunogenicity, which limited efficacy and was associated with severe infusion reactions. Subsequently chimeric, humanized, and fully human antibodies were introduced as therapeutics, these mAbs were considerably less immunogenic. Unexpectedly humanized mAbs generally show similar immunogenicity as chimeric antibodies; based on sequence homology chimeric mAbs are sometimes more “human” than humanized mAbs. With the introduction of the regulatory concept of similar biological medicines (biosimilars) a key concern is the similarity in terms of immunogenicity of these biosimilars with their originators. This review focuses briefly on the mechanisms of induction of immunogenicity by biopharmaceuticals, mAbs in particular, in relation to the target of the immune system. View Full-Text
Keywords: biopharmaceuticals; monoclonal antibodies; biosimilars; immunogencitity; B-cell tolerance; aggregates; anti-idiotypic biopharmaceuticals; monoclonal antibodies; biosimilars; immunogencitity; B-cell tolerance; aggregates; anti-idiotypic
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Doevendans, E.; Schellekens, H. Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies. Antibodies 2019, 8, 21.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top